Emphysema Treatment Global Market Report 2024

The emphysema treatment market has grown strongly in recent years. It will grow from $4.96 billion in 2023 to $5.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The expansion observed in the historical period can be ascribed to the impact of the smoking epidemic, advancements in medications, the implementation of pulmonary rehabilitation programs, enhanced diagnostic tools, and increased awareness and education.

The emphysema treatment market is expected to see strong growth in the next few years. It will grow to $6.85 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the forecast period can be linked to trends in the aging population, the adoption of customized treatment approaches, broader access to therapies, an emphasis on symptom management, and the implementation of collaborative healthcare models. Major trends expected in the forecast period involve the exploration of gene therapies, initiatives for patient education and empowerment, the integration of artificial intelligence (AI), improved accessibility to treatment, and the development of long-acting medications.

The anticipated increase in the prevalence of chronic obstructive pulmonary disease (COPD) cases is poised to drive the growth of the emphysema treatment market. COPD comprises a group of disorders, including emphysema and chronic bronchitis, leading to airflow obstruction and breathing difficulties. Emphysema treatments play a crucial role in mitigating the progression of COPD, focusing on symptom management, restoration of lung function, and delaying disease advancement. A study released by the Forum of International Respiratory Societies in September 2021 revealed that approximately 200 million people were diagnosed with COPD in 2021, with an annual mortality rate of around 3.2 million, ranking it as the third-leading cause of global mortality. Hence, the increasing prevalence of COPD cases is a driving force behind the emphysema treatment market.

The surge in air pollution is expected to contribute to the growth of the emphysema treatment market. Air pollution, characterized by the presence of harmful substances in the air, poses adverse effects on the environment and human health. Elevated levels of particulate matter and harmful gases in air pollution can exacerbate respiratory conditions, including COPD such as emphysema. The heightened exposure to air pollutants is likely to lead to an increase in respiratory diseases, fostering the demand for emphysema treatments. For example, in September 2021, IQAir, a Switzerland-based air quality technology company, reported a 25% rise in PM2.5 concentrations in Malaysia compared to the previous year. The recorded annual average for 2021, at 19.4 μg/m3, marked a significant increase of 3.8 μg/m3 from the levels observed in 2020. Consequently, the upsurge in air pollution is propelling the growth of the emphysema market.

Prominent companies in the emphysema market are striving to gain a competitive advantage by developing minimally invasive procedures tailored for emphysema patients. Minimally invasive procedures involve medical interventions or surgical techniques that aim to cause minimal disruption to the body's normal structures. For example, in January 2022, Adena Health System, a healthcare company based in the United States, introduced Zephyr Valve surgery as a minimally invasive alternative to traditional lung volume reduction surgery for individuals experiencing lung hyperinflation, a common issue in emphysema and COPD. This innovative procedure involves the placement of small, one-way Zephyr Valves in the lungs' airways through a bronchoscope. These valves facilitate the release of trapped air, preventing further accumulation and enabling healthier lung areas to expand, thereby improving breathing.

Leading companies in the emphysema market are also focusing on the development of innovative products, such as inhalation aerosols, to establish a competitive edge. Inhalation aerosols are pharmaceutical formulations dispensed as a fine mist or spray of liquid medication suspended in a propellant or propellant mixture. For instance, in July 2023, Viatris Inc., a U.S.-based pharmaceutical company, in collaboration with Kindeva Drug Delivery L.P., a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO), launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This marks the first FDA-approved generic version of AstraZeneca's Symbicort, catering to patients managing asthma, chronic obstructive pulmonary disease (COPD), and emphysema. Breyna, available in various dosage strengths, signifies a crucial advancement in providing accessible and cost-effective treatment options for individuals facing respiratory challenges.

In March 2023, UC Davis Health, an academic health institution based in the United States, entered into a collaboration with Propeller Health to offer individualized treatment for chronic obstructive pulmonary disease (COPD) and asthma through remote patient monitoring technology. This partnership allows UC Davis Health to provide eligible patients with Propeller Health's remote patient monitoring (RPM) service, delivering personalized therapy for high-risk COPD and asthma patients using sensors, a smartphone application, and a website. Propeller Health, a U.S.-based mobile platform company, provides sensors, mobile apps, analytics, and services to assist in respiratory health management.

Major companies operating in the emphysema treatment market report are AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Bioxyne Limited, Intrexon Corporation, iCure Pharmaceuticals Inc., Kamada Ltd., Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., British Technology Group International , Astellas Pharma Inc., Respinova Ltd., Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation.

North America was the largest region in the emphysema treatment market in 2023. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emphysema treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary treatments for emphysema include smoking cessation, bronchodilators, steroids, leukotriene modifiers, supplemental oxygen, antibiotics, gene therapy, surgery transplant, and others. Smoking cessation involves the cessation of smoking to reduce the risk of cancer and other significant health issues. This process helps minimize cravings and withdrawal symptoms while preventing nicotine binding. These treatments are available through various distribution channels, including online providers, drug stores, retail pharmacies, and hospital pharmacies. They are utilized by various end-users such as clinics, surgical centers, and others.

The emphysema treatment market research report provides emphysema treatment market statistics, including emphysema treatment industry global market size, regional shares, competitors with an emphysema treatment market share, detailed emphysema treatment market segments, market trends and opportunities, and any further data you may need to thrive in the emphysema treatment industry. This emphysema treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The emphysema treatment market includes revenues earned by entities by providing medical services such as bronchodilator medications, anti-inflammatory medication, oxygen therapy, lifestyle change consultation, and interventional therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.